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 drug delivery m
ethod for infants is presented w
hich incorporates an active pharm
aceutical 
ingredient (A






PI is released directly 
into m
ilk during breastfeeding. This study investigates the feasibility of using the N
SD
S to deliver the 
m
icrobicide sodium
 dodecyl sulfate (SD
S), w






 during breastfeeding in low
-resource settings, w
hen there is no safer alternative for the 
25 
infant but to breastfeed. SD
S has been previously show







as developed to sim
ulate m
ilk flow







as pulsed through a prototype device containing a non-w




S and the m
icrobicide w
as rapidly released. The total SD
S release from
 inserts ranged from
  
70-100%
 of the average 0.07 g load w
ithin 50 m
l (the volum










as also passed through the sam
e set-up. G
reater than 99%




as achieved in the first 10 m
l of m
ilk. This proof of concept study 
dem










































































There is no single suitable drug and nutrient delivery m
ethod available for infants or young children 
(K
earns et al., 2003). In developing countries w
here m
edical infrastructure is often scarce, pediatric drug 
and nutrient delivery system
s face num






, 2010c). Liquid form
ulations are often the principal m
ethod of pediatric 










ulations are not available, a solid dosage form
 





edicines are only 




onati, 2005; Stoltenberg et al., 2010).  A
dditionally, liquid form
ulations can be 
unpalatable especially for young infants and m
ay require undesirable toxic excipients, such as preservatives 
and solvents. There is a clear need for form
ulations that are appropriate, safe, and effective for children. 
O
ne clear exam
ple of the need for appropriate m










500,000 infants per year w





others, it is estim
ated that 200,000 infants 
are infected through breastfeeding (C
hasela et al., 2010), w
ith 90%
 of M









 policy on breastfeeding states that, ‘…
w
hen replacem
ent feeding is 









, 2010b). This condition is often not m
et, and breastfeeding in  
65 
low
-resource settings has been show









end the continued use of oral anti-retroviral (A
RV
) 
drugs by the m
other and/or the infant to prevent H
IV
 transm







idespread distribution of A
R
V
s does not yet exist in Sub-Saharan A
frica and A
RV
 use can lead 
to side effects and resistant strains of the virus if infection still occurs (Zeh et al., 2011).  
70 
A
s an alternative approach, the adm
inistration of edible m
icrobicides into expressed infected m
ilk w
hich is 
then delivered to the baby has been previously considered (H
artm
ann et al., 2006a). Sodium
 dodecyl (or 
lauryl) sulfate (SD







ilk. It has been dem
onstrated that 0.1 – 1 w
t%
 SD







ett et al., 2000, 1999; K






S has been dem











 acceptable infant oral exposure to SD
S of 1 g/kg (of infant)/day and an biochem
ical analysis of 




ann et al., 2006a, 2006b).  A
nother benefit of SD
S is its broad 
antiviral activity by solubilizing lipid m
em





strain independent and unlikely to drive H
IV
 m
utation to a resistant form
 (H
artm
ann et al., 2006b).  
G
iven that delivery of SD
S during breastfeeding m
ay be an effective m






e propose a new
 m
ethod to deliver SD
S to infants during breastfeeding 
that also overcom
es m
any of the general challenges associated w
ith frequent drug delivery to infants. The 
concept is to incorporate a drug-im
pregnated insert into a nipple shield w
orn by a m
other during 
85 
breastfeeding (Fig. 1), w
here during suckling, a drug is released directly into the m
ilk (G
errard, 2011; 
Sokal et al., 2009). N
ipple shields, typically a single m
olding of silicone, are available at low
 cost and are 
used to aid m
others and/or infants during breastfeeding, typically to reduce pain or nipple dam
age, or to 
assist latching on (R
iordan, 2005). The N
SD
S w
ould have an insert containing a dose of the A
PI in dried 
form














as her child breastfeeds, and as m
ilk passes through the insert the A
PI w
ould be released directly into the 
m
ilk and pass to the infant. The insert could be placed inside the N
SD
S prior to each feed or the N
SD
S 
could be preloaded w
ith the insert prior to the m




S could be w
ashed, disinfected, and reloaded w
ith another insert for reuse.  
95 
This study had tw
o aim
s: firstly to determ





during a pulsed flow
 that m
im
ics breastfeeding; and secondly to establish w







ilk can inactivate H
IV
 w






















S inserts, 10 m
m
 diam
eter discs of a m
edical grade non-w
oven cellulosic (viscose) and 
polyester based fiber m
atrix w
ith a 2.75 m
m
















solution at 60 °C
 for 10 seconds. They w
ere then air dried at room
 tem
perature on a m
esh. A
fter 72 hours 
drying their w
eight stabilized w
ith a final w
eight gain of 0.07 g (standard deviation 0.01 g, n = 13). This 
105 
fiber grade w
as chosen because it is non-toxic, suitable for flow
 w
ith low
 back pressure, and it is easy to 
load a com
pound such as SD
S onto it. 
2.2 K
inetics of SD
S release into m
ilk in sim
ulated breastfeeding conditions 
To sim
ulate use of a N
SD
S to deliver SD
S during breastfeeding, loaded inserts w





-ring, 3/8 ” ID
, U
K
) to seal them












ere placed directly into the holder (0.1 g). Sam
ple fluids w
ere 
passed through a peristaltic pum
p (M







), heated to 37 °C
 by passing through tubing in a w
ater bath held at 42 °C
, and then 
delivered through the SD
S loaded device. A
round 50 x 1 m




through using a SuperFrac









ed in a feed (K
ent et al., 2006). The m
ilk reservoir w
as continuously stirred to prevent fat 
accum
ulating at the top inlet. Individual fractions w
ere assayed in triplicate for SD
S concentration using a 
colorim
etric assay described below
.  
SD
S concentration in m
ilk fractions w
as m
easured using an adapted stains-all colorim
etric assay (R
usconi 
et al., 2001). The assay relies on the shift in absorbance at 438 nm
 w





S. The stains-all reagent underw








ably caused by interactions w
ith lipids, proteins or com
ponents w








as added. Thus, by 
diluting m
ilk sam
ples to a fixed ratio in w
ater prior to testing, keeping the absorbance signal caused by 
m
ilk alone constant, the absorbance at 438nm
 w









ilk (Fig. 3). A
 range of dilution factors w
ere used to accurately 
detect concentrations of SD
S in m
ilk above 0.03 w
t%
. SD
S concentration in test sam
ples w
as calculated by 
com
parison to calibration curves m
easured at the sam
e sam













ilk, either pasteurized but not hom
ogenized (Taste the D
ifference Jersey M
ilk, 5.2%





























ake an assay solution sufficient to analyze 250 sam
ples, 20 m






as dissolved in 1 m
l follow
ed by a further 19 m
l of 1:1 isopropanol:w
ater, follow




ater to a total volum
e of 380 m
l plus the addition of 20 m
l form
am
ide and thorough m













ater. Triplicate 25 μL sam
ples of each diluted fraction w
ere m
ixed w
ith 1000 μL 
stains-all stock solution follow
ed by m
easurem
ent of absorption at 438 nm





ean absorbances plotted, and unknow







ere used outside the range of linearity w
ith typical 
correlations of R










S insert  
To determ































S inserts using a near identical setup to 
that used to m
easure SD
























IIIB  cells are self replicating cells that express H
IV
 (type-1 IIIB
), and have been 
150 
previously used to m
odel cell-associated H
IV
 (Lara et al., 2011; Y
am
aguchi et al., 2007). The cell content 
spiked in m
ilk w
as based on previously reported concentrations of betw




ith typical total cell concentrations in the first few
 days of life to be 10
6 cells/m
l (N
duati et al., 
1995; R
ousseau et al., 2004). Prior to being spiked in m
ilk, the cells w
ere centrifuged at 1500 R
PM
 for 5 
m
inutes and re-suspended in cell culture m
edia to rem
ove free virus. 5 m
l m
ilk fractions w














-bl cells are H





4 receptors and 
indicate H
IV
 infectivity via a luciferase reporter (M
ontefiori, 2005). Infectivity values w






n infectivity for concentrations of H
9/H
IV
IIIB  cells in the 
sam
e m
ilk (Fig. 6a).  
160 
The concentrations of SD
S released into early m
ilk fractions, and the hum
an m
ilk itself, w
ere both found to 
disrupt the TZM




 infectivity in the fractions. 







IIIB  cells 20 m
inutes after 
fraction collection, by 3 rounds of centrifugation and w
ashing in cell culture m
edium












S at all release concentrations to prevent direct disruption of TZM
-bl cells w
ith the donor m
ilk used 
(data not show
n). This protocol also prevented H
IV











ould not be representative of the conditions 
encountered by cell-associated H
IV
 passing through the N
SD




ere diluted 1:10 (vol.) in cell culture m




ed plate (# 3799, C
orning, U
SA
), centrifuged (1500 R
PM
 for 5 m



































ashing, 25 µL of culture 
m
edium
, 25 µL w
ashed sam
ple and 50 µL TZM
-bl cells at 2 x 10
5 cells/ m
l w




















as added to TZM
-bl cells just prior to 
sam











as added and lum
































using the apparatus outlined in section 2.2 and Fig. 2d. This w
as perform
ed to provide evidence of the 
influence of the physiological variables w








ined a suitable apparatus to m
im
ic drug release from










ere achieved by 
m
aintaining the m
ilk at 37 °C
 and using a peristaltic pum
p to produce pulsed flow
 to sim
ulate the suction 
pressure created by a baby (Fig. 2d). D
uring breastfeeding, pulse rate and volum




e of 0.07 m
l per pulse w
as chosen that lies w
ithin the typical range of a feeding 
190 
infant (Zoppou et al., 1997); this corresponds to a flow
 rate of 4.2 m
l/m
in. Total feeds have been reported 
to have a m
ean of 76 g (std. dev. 12.6 g) and a range of 0-240 g per feed, i.e. m
ean 74 m
l and range  
0-233 m
l per feed given a reported density of hum
an m
ilk of 1.03 g/m
l (K








as developed to produce an insert w
ith total load of 0.7 g SD
S,  a 
195 
sufficient quantity to release an effective m
icrobicidal concentration to rapidly inactivate H
IV




hile keeping the total SD
S load w
ithin acceptable daily doses (H
artm
ann et al., 
2005, 2006a, 2006b).  
The spectrophotographic assaying m
ethod outlined in section 2.2 and Fig. 3 w
as used to detect SD
S for all 
release tests. W
hen flow
 conditions, insert loading, and m
ilk type and batch w




ere highly reproducible confirm
ing that the apparatus is suitable for release studies 
(Fig. 4, Fig. 5 and data not show
n). G





individuals and even during feeds from
 the sam
e individual (D
aly et al., 1993; K







’s and goat’s m
ilk w

















on release pattern presented itself: the highest am
ounts of SD
S releasing into early fractions, 
follow
ed by decreasing concentration over tim
e, indicating approxim




as fitted to the cum
ulative release data for each experim
ent to qualify this observation (see section 
3.4).  
210 
3.2 Effect of flow
 conditions and tem
perature and insert form
 on release kinetics 
The initial focus w
as to identify the principal release behavior of SD
S from
 the non-w
oven fiber over a 
range of flow
 conditions. This w
as intended to exam
ine the basic influence of fluid kinetics on release 
behavior, w
hich m
ay vary significantly from
 a feeding infant using the N
SD
S.  
The effect of m
ilk tem
perature upon release behavior w




perature for future laboratory studies.  The release of SD
S from
 the non-w













ilk)  into hom
ogenized, pasteurized cow
’s m




as detected after 30 m
l in all tests. This suggests that m
ilk tem
peratures betw
een 16 and  
37 °C
 m
ight not significantly influence SD




The influence of tw




een tests: the pulse rate (how
 quick the 




ilk is extracted from
 the breast per suck); these w
ere 
controlled by altering the size of tubing used by the peristaltic pum
p and the operating speed. Tw
o test sets 
w




aintaining the pulse rate at 60 pulses/m
in 
and varying pulse volum
e at 0.02, 0.07 and 0.45 m
l/pulse and (2) m
aintaining the pulse volum
e at  
225 
0.07 m
l/pulse and varying the pulse rate to 40, 60 and 80 pulses/m








ilar rates for all these flow
 rate conditions, w
ith 
>50%
 of release of the disc’s load after 20 m
l for all tests (Fig. 4c and d). SD




S (previously reported to be highly anti-viral – see 1. Introduction) w
ere seen for the tests in the 
first 20 m
l of m
ilk that passed through the non-w
oven fiber insert.   
230 
The influence of the non-w







placed into the insert holder.  0.1 g of SD
S pow
der w
as used per test. Sim





oven fiber insert experim








 after 50 m
l for 16 °C




 for 37 °C
 for the 
sam
e m
ilk source (Fig. 4e).  
235 
3.3 Effect of m
ilk com
position on release kinetics 
The influence on release behavior due to m
ilk com
position w





ith varying pasteurization and hom
ogenization.  A
nalysis of initial release behavior provided 
a suitable m
arker for the effect of different fluid types. A
pproxim
ately 100%
 of the insert load had released 
into non-hom










 into the non-hom
ogenized pasteurized form
, suggesting progressively slow
er release into 
these respective fluids (Fig. 5). The m
ean volum
e needed for 50%





een these 3 fluids w
as also com
pared, and goat’s m
ilk (average 1.4 m
l) induced 
significantly m
ore rapid release than both hom
ogenized pasteurized (5.1 m
l) (p < 0.05) and non-
hom
ogenized pasteurized (16.3 m
l) (p < 0.1) cow
’s m
ilk (using unpaired tw










as not significant 
(p > 0.05).  The observed difference in cow
’s and goat’s m
ilk release behavior indicates that m
ilk 
com
position significantly influences release kinetics 
3.4 M
odeling release behavior 
For an initial m
odel it w
as proposed that total drug release w





































ass fraction of SD











 the start of the test until a volum





















sing Eq. (2) for each release test k
1  and k
2  w
ere varied to optim
ize the least squares value using a 
com
putational non-linear regression analysis optim
ization algorithm











st order release kinetics m
odel presented R
2 > 0.969 for all tests apart from
 one w




2 at 0.933 (Table 1.). This indicates that for m
ost flow




st order release kinetics. For non-w
oven fiber tests under the sam
e flow
 conditions (Table 2.) 
the constant k
2 w






ilk (0.141-0.181) to hom
ogenized cow
’s m
ilk (0.036-0.069). The m
ean k




een all fluids (p < 0.05) using unpaired, tw
o tailed t-tests. k
2 , w
hich indicates rate 
of release, w










 release expected by 1
st order release kinetics. G
iven the total cum






1  values derived by regression analysis w
ere found to be close to 1. 
Further tests are needed to expand the m




ilk influence the 
265 
rate of release.  
3.5 H
IV




For the final elem





studied using the sam




the anti-viral concentrations of SD
S found to release into various m





ould be expected in hum
an m
ilk, and thus the N
SD




 infectivity at least in the first portion of m
ilk passed through the insert.  
It has been previously argued that cell-associated H
IV
 m
ay have the predom





ousseau et al., 2004) so cell associated H
IV
 w





ere used as a m
odel of cell-associated H
IV
. The cells w












ere then passed through SD
S-loaded N
SD
S inserts at 60 pulses/m
in and 
0.07 m
l/pulse (used in release tests and typical of infant feeding conditions, see section 3.1). TZM
-bl cells 
w
ith luciferase reporter genes w
ere used to m
easure the infectivity of H
9/H
IV
IIIB  cells before and after the 
tests. Since exposure of TZM
-bl cells to both hum
an m
ilk and SD




IIIB  cells, an assay w
as developed that allow
ed m
easurem



















 infectivity (see section 2.3).  
W
hen know
n doses of H
9/H
IV









IIIB  cell concentrations betw
een 0.26 x 10
4 – 26 x 10
4 cells/m
l w
ere quantitatively detected, 
indicating a sensitive assay of H
IV
 infectivity (Fig. 6a). R
elative H
IV














exposed to test sam
ples w
ith the calibration data in Fig. 6a. U
sing this m
ethod, it w










S-loaded insert resulted in a significant reduction in the 
m
ean correlated infected cell content of 3 tests, com
pared to input cell content (Fig. 6b). A
verage infectious 
cell content reductions w
ere significant at the follow
ing levels: M
ore than 2 log reduction for 0-5 m
l  
290 
(p < 0.0001), 1.5 log reduction for 5-10 m
l (p < 0.0001) and 0.6 log reduction for 10-15 m
l (p < 0.05) 
(using paired single tailed t-tests). A
 0.4 log reduction for 15-20 m
l, 0.4 log reduction for 20-25 m
l and  
0.3 log reduction for 25-30 m
l in m
ean infected cell content w
as observed but these reductions w
ere not 
significant (p  > 0.05). The individual infectious cell content in each volum
e fraction is illustrated in Fig. 
6b. The sm
all variation in reduction of infectivity betw
een repeat tests is likely due biological variations in 
295 
inactivation betw
een tests, given the sm
all variance observed betw
een replicate H
IV
 infectivity assays of 























 conditions and solvent type. For this study w
here flow
 conditions and m
ilk type 
w
ere changed the greatest variation in release behavior w
as seen betw




ilk producing the m
ost rapid SD
S release rate. U
nderstanding in detail the effect of m
ilk 
com
position on release kinetics w
ill be im





to have highly variable com
position; for exam
ple during a typical feed, the fat content can increase by up to 
305 
3-fold (D
aly et al., 1993).  
In order to obtain consistent drug release betw
een m
others despite their varying m
ilk content, it m
ay be 




 rate-independent release kinetics for 
various m
ilk com
positions possible in feeding. Further form
ulation m
ethods should be considered for SD
S 
and other A
PIs. They could include m




the fiber or using a different support m





onstrated that addition of hydroxym




ay result in slow
er SD
S release into m
ilk and reduce the initial high release that 
appears to be highly com
position dependent (unpublished observations). A
lternatively, SD
S or other A
PIs 
m
ight be incorporated in the fiber during m
anufacturing, to further control release as seen in related studies 
315 
(C
ui et al., 2006).  
The first-order cum
ulative release m
odel presented fitted our observed data w
ell, and the constants derived 
by regression analysis supported the observation that the m




l, and that m
ilk com







pass all the factors influencing release from
 the non-w





odel fitted least w
ell; further w
ork is required to refine the m
odel. W
e postulate that a 
com
bination of dissolution phenom
ena and solid and hydrated particulate release from
 the fibers govern 
SD
S release from
 fibers.  
4.2 V














ed by a m
uch sm
aller reduction in later fractions. The 
reported threshold of rapid H
IV
 inactivation (> 0.1 w
t%
) also occurred w
ithin the first 10 m
l of release for 
goat’s m




ann et al., 
2006a, 2006b, 2005). This suggests that the initial high release behavior of SD
S observed in goat’s m
ilk 
m
ay also have occurred w
ith hum
an m
ilk and therefore goat’s m
ilk m
ay be a suitable m
im




S release studies. Further w
ork is needed to understand w
hat com
ponents affect SD




position affects release kinetics before a suitability-of-use analysis can be 
m
ade.   
The im




ilk for prevention of M
TCT can only be 
speculated about at this point. M
TCT of H
IV






ay occur either through the free virus or cell-associated virus, w
ith possible sites of 
transm
ission including the m
ucosal surfaces of the tonsils and gut (C
avarelli and Scarlatti, 2011). Thus the 
SD
S release rate into m
ilk m
ay alter transm
ission rates depending on w
here anti-viral concentrations of 
SD
S in the digestive system
 reside during the feed. The proof of concept data in this paper should provide 
an indication of how
 cell-associated H
IV
 could be inactivated by SD





ay act on both free virus and infected cells during their passage through the digestive system
, 
and SD





ed later in the feed. 
This w
ould lead to a higher reduction of H
IV
 infectivity than that seen in this sim
plified study.  Further 
study w






ne key advantage of SD
S over other anti-viral com






ann et al., 2005); this rapid inactivation m
ay reduce viral load in infected m
ilk before 
it even reaches proxim
al sites of infection such as the oral m
ucosal tissues of the infant. 







ay also be a viable 
consideration for preventing M
TCT of H
IV








 et al., 2011, 2008). This could be com
bined w
ith m
icrobicide release to 
potentially increase viral inactivation using a N
SD
S.  
4.3 Future uses of the N
SD
S 
The acceptability of a N
SD
S to breastfeeding m
others m
ust be carefully assessed prior to use.  For its 
specific use in preventing M
TCT of H
IV
 during breastfeeding a study w




and stakeholders involved in deciding infant feeding practices w
ere questioned, and gave positive feedback 
about the potential use of a N
SD
S to prevent H
IV
 transm
ission in feeding (Israel-B
allard et al., 2010). 
For any specific application, careful consideration w
ill be needed to determ
ine if a disposable single use 
device or a re-useable one, w








ore sustainable and low







ited, the feasibility of ensuring hygienic device re-use w





S delivery a w
ide range of individual or com
binations of m
edicinal substances could be 
delivered to infants using the N
SD
S, including drugs such as antibiotics and antim
alarials, or vitam
ins, 
nutrients and probiotics. Sim
ilar inserts could be incorporated into m
odified bottle teats, allow
ing equally 
365 
effective drug delivery to infants fed w
ith form
ula or expressed m




S to deliver agents other than m
icrobicides w
ill generally require sim
ple direct A
PI release 
rather than potentially sustained release, w
ith the prim
ary focus to ensure full dose release w
ithin a typical 
feed. Taste, solubility and the effect of the form




considerations, and alternative insert form
s such as tablets should be considered.  
370 
Potential advantages of the N
SD
S over other infant drug delivery routes and devices include ease of use 
and precise dosing com
pared w
ith drops or spoon-fed liquids. A
lternatives to parenteral delivery are 
particularly im
portant for frequently adm
inistered drugs because of the burden on trained healthcare 
w
orkers, the risks associated w
ith needle use, and to avoid pain associated w







proving acceptability for the infant. Furtherm
ore, for labile A




proved stability over liquid form
ulations. D
rug adm
inistration during breastfeeding 
m
ay also increase the bioavailability of som
e drugs (Charkoftaki et al., 2010). 
 A
dditional benefits of the N
SD
S in low




 level of training needed for correct dosing, potential for a single-use disposable device 
avoiding requirem
ent for sterilization, and a robust dry form
ulation for therm














hich is often the safest m
ethod of infant feeding even w
hen the m
























S placed over the m
other’s breast, is proposed to be an effective m
ethod for oral delivery of 
m
icrobicides to prevent M
TCT of H
IV
. This study has dem
onstrated that a N
SD





oven fiber insert at non-toxic m
icrobicidal concentrations. It has also dem
onstrated that 
SD
S release using the N
SD
S is capable of rapidly inactivating significant am







S is especially valuable for use in developing countries w
here no safer alternative 
390 
to breastfeeding exists. Future w






position, the addition of cellulose based com
pounds 
onto the fiber, or the addition of m
icrobicides and cellulose in fiber construction, m
ay enable controlled 
release patterns. W
ith better understanding of the sites of transm
ission in breastfeeding these m
ethods 
could be adapted to m
axim
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 conditions. Fitted m
odel param
eters 
to a first-order release kinetic m






















































































































’s and goat’s m
ilk for constant flow






S-fibre insert. Fitted m
odel param
eters to a first-
order release kinetic m
odel according to Equ. (2) also displayed. 
 








ilk leaving breast passing through nipple shield delivery system
 insert. 
Fig. 1. N
ipple shield delivery system
 for oral drug delivery to breastfeeding infants  
(Im
ages provided courtesy of http://justm
ilk.org) (a) N
on-w
oven fiber inserts. (b) D
em
onstration of 
blister pack containing replaceable inserts. (c) A
 m
odified silicone nipple shield adapted to hold inserts in 
place during breastfeeding (prototype, not for clinical use).  
420 
Fig. 2. M
ethods for studying SD
S release into m
ilk in pulsed flow
 conditions  
(a) The fiber insert sealed into the housing w
ithin an o-ring. (b) The assem




oven fiber insert housed w
ithin an o-ring. (d) D
iagram
 of rig used to deliver pulsed 
flow
s of m











S concentration in m
ilk using stains-all dye 




n concentrations of SD
S dissolved either in (a) w
ater or 
m
ilk subsequently diluted in (b) 1:10 w
ater dilution or (c) 1:100 w
ater dilution. A
 clear linear relationship 
betw
een absorbance and SD





S release into m
ilk over a range of concentrations. D
ata representative of >20 
430 
experim
ents; fresh standard curves w
ere prepared for every release experim
ent using the sam
e batch and 
type of m
ilk tested to determ
ine SD














S loaded onto non-w






ined. (a, b) The effect of tem
perature on release at a flow
 rate of 4.3 m
l/m
in 
and pulse rate 60 pulses/m
in w
as determ
ined. (c) The effect on release of varying pulse volum
e at a fixed 
pulse rate of 60 pulses/m
in w
as determ











 at a flow
 rate of 4.3 
m
l/m




ata displayed as (i) concentration of SD
S in 
440 
individual collected 1 m
l fractions and (ii) cum
ulative SD
S release relative to input SD
S load. In all cases, 
each set of sym
bols represents an individual release experim
ent,  w
ith the m




S concentrations for each fraction show
n. 
Fig. 5. Effect of m
ilk type on SD
S release kinetics 
The release of SD
S from
 loaded non-w
oven fibre discs during pulsed flow








ilk and (c) non-hom






 rate of 4.3m
l/m
in and pulse rate of 60/m
in. D
ata are displayed as concentration of 
SD
S in collected 1 m
l fractions (i) and cum
ulative SD
S release relative to input disc load (ii). In all cases, 
each set of sym
bols represents an individual release experim
ent, w
ith the m





















IIIB  cell content in m
ilk; TZM
-bl reporter cells w
ere 
infected w
ith a range of H
9/H
IV
IIIB  cell concentrations in m
ilk and assayed for infection by lum
inescence 




-bl cell infection by H
9/H
IV




easured after passage of the m
ilk plus cells through SD
S-containing non-w
oven fiber inserts. 
455 
R




IIIB  cells, calculated using the 
calibration assay show
n in (a). 3 repeat experim
ents w
ere perform
ed and individual data plotted for all 
experim
ents; all used a fluid flow
 rate of 4.3 m
l/m
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